| Targeting MYCN in neuroblastoma by BET bromodomain inhibition A Puissant, SM Frumm, G Alexe, CF Bassil, J Qi, YH Chanthery, ... Cancer discovery 3 (3), 308-323, 2013 | 701 | 2013 |
| Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation A Puissant, G Robert, N Fenouille, F Luciano, JP Cassuto, S Raynaud, ... Cancer research 70 (3), 1042-1052, 2010 | 431 | 2010 |
| Metformin inhibits melanoma development through autophagy and apoptosis mechanisms T Tomic, T Botton, M Cerezo, G Robert, F Luciano, A Puissant, P Gounon, ... Cell death & disease 2 (9), e199-e199, 2011 | 342 | 2011 |
| When autophagy meets cancer through p62/SQSTM1 A Puissant, N Fenouille, P Auberger American journal of cancer research 2 (4), 397, 2012 | 316 | 2012 |
| The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia L Willems, N Chapuis, A Puissant, TT Maciel, AS Green, N Jacque, ... Leukemia 26 (6), 1195-1202, 2012 | 182 | 2012 |
| In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling PG Miller, F Al-Shahrour, KA Hartwell, LP Chu, M Järås, RV Puram, ... Cancer cell 24 (1), 45-58, 2013 | 179 | 2013 |
| Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death I Ben-Sahra, B Dirat, K Laurent, A Puissant, P Auberger, A Budanov, ... Cell Death & Differentiation 20 (4), 611-619, 2013 | 163 | 2013 |
| Autophagy, a key mechanism of oncogenesis and resistance in leukemia P Auberger, A Puissant Blood, The Journal of the American Society of Hematology 129 (5), 547-552, 2017 | 154 | 2017 |
| SYK is a critical regulator of FLT3 in acute myeloid leukemia A Puissant, N Fenouille, G Alexe, Y Pikman, CF Bassil, S Mehta, J Du, ... Cancer cell 25 (2), 226-242, 2014 | 152 | 2014 |
| Targeting MTHFD2 in acute myeloid leukemia Y Pikman, A Puissant, G Alexe, A Furman, LM Chen, SM Frumm, L Ross, ... Journal of Experimental Medicine 213 (7), 1285-1306, 2016 | 133 | 2016 |
| Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML O Lindblad, E Cordero, A Puissant, L Macaulay, A Ramos, NN Kabir, ... Oncogene 35 (39), 5119-5131, 2016 | 116 | 2016 |
| Autophagy is an important event for megakaryocytic differentiation of the chronic myelogenous leukemia K562 cell line P Colosetti, A Puissant, G Robert, F Luciano, A Jacquel, P Gounon, ... Autophagy 5 (8), 1092-1098, 2009 | 116 | 2009 |
| Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death G Robert, I Ben Sahra, A Puissant, P Colosetti, N Belhacene, P Gounon, ... PloS one 4 (11), e7889, 2009 | 108 | 2009 |
| AMPK-and p62/SQSTM1-dependent autophagy mediate resveratrol-induced cell death in chronic myelogenous leukemia A Puissant, P Auberger Autophagy 6 (5), 655-657, 2010 | 99 | 2010 |
| The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia N Fenouille, CF Bassil, I Ben-Sahra, L Benajiba, G Alexe, A Ramos, ... Nature medicine 23 (3), 301-313, 2017 | 98 | 2017 |
| Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors S Grosso, A Puissant, M Dufies, P Colosetti, A Jacquel, K Lebrigand, ... Molecular cancer therapeutics 8 (7), 1924-1933, 2009 | 94 | 2009 |
| Targeting autophagy to fight hematopoietic malignancies A Puissant, G Robert, P Auberger Cell Cycle 9 (17), 3470-3478, 2010 | 93 | 2010 |
| SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival N Fenouille, A Puissant, M Tichet, G Zimniak, P Abbe, A Mallavialle, ... Oncogene 30 (49), 4887-4900, 2011 | 88 | 2011 |
| BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients T Cluzeau, G Robert, N Mounier, JM Karsenti, M Dufies, A Puissant, ... Oncotarget 3 (4), 490, 2012 | 86 | 2012 |
| Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia FF Wagner, L Benajiba, AJ Campbell, M Weïwer, JR Sacher, JP Gale, ... Science translational medicine 10 (431), eaam8460, 2018 | 85 | 2018 |
